Guides

Summary

The document explains the CRO and CDMO outsourcing markets, their role in drug development, and why India is an important hub. It also provides market size estimates for the global and Indian CRO/CDMO segments, along with the main growth drivers, including rising R&D, complex therapies, cost pressure, and regulatory needs

It highlights that both the global and Indian markets are growing, with India showing strong potential due to its skilled workforce, patient pool, and cost advantage. Oncology is the leading therapeutic area, while other important areas include infectious diseases and metabolic disorders.

Yet, despite India’s strengths, global companies repeatedly face execution barriers in the region not due to scientific gaps, but due to governance blind spots, inconsistent oversight, regulatory misalignment, and variable vendor maturity.